Systematic identification of small molecule adjuvants
- 24 June 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 7 (9) , 807-817
Abstract
Adjuvants potentiate immune responses, reducing the amount and dosing frequency of antigen required for inducing protective immunity. Adjuvants are of special importance when considering subunit, epitope-based or more unusual vaccine formulations lacking significant innate immunogenicity. While numerous adjuvants are known, only a few are licensed for human use; principally alum, and squalene-based oil-in-water adjuvants. Alum, the most commonly used, is suboptimal. There are many varieties of adjuvant: proteins, oligonucleotides, drug-like small molecules and liposome-based delivery systems with intrinsic adjuvant activity being perhaps the most prominent. This article focuses on small molecules acting as adjuvants, with the author reviewing their current status while highlighting their potential for systematic discovery and rational optimisation. Known small molecule adjuvants (SMAs) can be synthetically complex natural products, small oligonucleotides or drug-like synthetic molecules. The author provides examples of each class, discussing adjuvant mechanisms relevant to SMAs, and exploring the high-throughput discovery of SMAs. SMAs, particularly synthetic drug-like adjuvants, are amenable to the plethora of drug-discovery techniques able to optimise the properties of biologically active small molecules. These range from laborious synthetic modifications to modern, rational, effort-efficient computational approaches, such as QSAR and structure-based drug design. In principal, any property or characteristic can thus be designed in or out of compounds, allowing us to tailor SMAs to specific biological functions, such as targeting specific cells or pathways, in turn affording the power to tailor SMAs to better address different diseases.Keywords
This publication has 104 references indexed in Scilit:
- Systemic Administration of CpG Oligodeoxynucleotide and Levamisole as Adjuvants for Gene-Gun-Delivered Antitumor DNA VaccinesJournal of Immunology Research, 2011
- Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88Proceedings of the National Academy of Sciences, 2011
- Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activationProceedings of the National Academy of Sciences, 2011
- Dectin-1: a role in antifungal defense and consequences of genetic polymorphisms in humansMammalian Genome, 2010
- Identification of Novel Synthetic Toll-like Receptor 2 Agonists by High Throughput ScreeningJournal of Biological Chemistry, 2010
- Toward the Discovery of Vaccine Adjuvants: Coupling In Silico Screening and In Vitro Analysis of Antagonist Binding to Human and Mouse CCR4 ReceptorsPLOS ONE, 2009
- Mechanism of action of clinically approved adjuvantsCurrent Opinion in Immunology, 2009
- In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccinationProceedings of the National Academy of Sciences, 2008
- Synthetic oligonucleotides as modulators of inflammationJournal of Leukocyte Biology, 2008
- Phosphorothioate-Modified Oligodeoxynucleotides Inhibit Human Cytomegalovirus Replication by Blocking Virus EntryAntimicrobial Agents and Chemotherapy, 2008